Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 16/20 | 0.56 |
| ▸ | HTR1D | P28221 | 16/20 | 0.56 |
| ▸ | HTR1B | P28222 | 16/20 | 0.56 |
| ▸ | HTR2A | P28223 | 7/20 | 0.55 |
| ▸ | HTR2C | P28335 | 6/20 | 0.55 |
| ▸ | HTR6 | P50406 | 5/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14596986 | 0.96 | HTR1A (0.60) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| SCHEMBL14596951 | 0.91 | HTR1A (0.55) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| SCHEMBL14596957 | 0.86 | HTR1A (0.50) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| SCHEMBL14596958 | 0.86 | NPC1 (0.53) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| SCHEMBL14596982 | 0.86 | HTR1A (0.52) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| SCHEMBL14596964 | 0.85 | HTR1A (0.49) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| SCHEMBL14627785 | 0.85 | HTR1A (0.51) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| SCHEMBL5452315 | 0.84 | HTR1A (0.49) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| SCHEMBL14596983 | 0.84 | CA1 (0.60) | HTR1AHTR1DHTR1BHTR2AHTR2C | |
| SCHEMBL14596943 | 0.83 | HTR1A (0.49) | HTR1AHTR1DHTR1BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | HTR1A 3/4885HTR1D 2/4885HTR1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.